Commercialization News

If you’re looking to stay up to date with the latest commercialization news out of the Office of Research and Technology Management at Case Western Reserve University, you’ve come to the right place. Explore some of our latest headlines relating to inventions, startups and more from researchers at CWRU.


2025

Symphony Robotics Licenses New Robotics Technology to Fight Brain Tumors
BusinessWire | Feb. 11, 2025

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
NervGen | Feb. 6, 2025

Neuros Medical and Veterans Healthcare Supply Solutions Partner to Provide Revolutionary Treatment for Chronic Post-Amputation Pain to Veteran and Active-Duty Military Amputees at VA Healthcare and Military Treatment Facilities
PR Newswire | Feb. 5, 2025

Inspired by hedgehogs: Atelerix’s €894k funding to innovate biosample storage and transportation
EU-Startups.com | Jan. 28, 2025

Biotech firm CollaMedix charts big growth in new Cleveland facility
Crain’s Cleveland Business | Jan. 17, 2025

Electronics Scrap Recycling Advancement Prize

Energy.gov | Jan. 8, 2025


2024

University Hospitals Haslam Sports Innovation Center Makes First Investments in Sports Medicine Innovation
University Hospitals | Dec. 17, 2024

Digital Storage And Memory Projections For 2025, Part 2
Forbes | Dec. 11, 2024

Two New Solutions from Hemex Health Empower More Clinicians and Health Workers to Test for Iron Deficiency Anaemia and Sickle Cell Disease
Global NewsWire | Nov. 14, 2024

ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics
PR Newswire | Oct. 29, 2024

Seasoned startups: MAGNET Mspire pitch competition puts mature companies in spotlight
FreshWater | Oct. 24, 2024

Biohm and ADM partner on microbiome formulation for women
NutraIngredients USA | Oct. 16, 2024

Twelve-Month Results from Landmark QUEST Study Published in Neuromodulation
PR Newswire | Sept. 26, 2024

NIH Awards Kevin Kilgore, PhD, $2.2 Million in Grants
MetroHealth | Sept. 9, 2024

Neuros Medical Receives FDA Approval for the Altius® Direct Electrical Nerve Stimulation System
PR Newswire | Aug. 28, 2024

Robotic street painter takes over Downtown Cleveland, saving the city manpower and cash
News 5 Cleveland | Aug. 22, 2024

Phase 1 BAFF CAR T Clinical Trial for Patients with Relapsed and Refractory Multiple Myeloma Underway at UH Seidman Cancer Center
University Hospitals | Aug. 9, 2024

Chemical engineer Rohan Akolkar earns top honors from ECS
The Daily | July 12, 2024

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
NervGen | June 25, 2024

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation
WKYC | April 21, 2024

Mission Possible: Case Western, Cleveland company research creating artificial blood
DefiniGEN | June 3, 2024

Beachwood’s strategic focus on local business growth attracts innovation to Commerce Park
Crain’s Cleveland Business | March 18, 2024

BIOHM Health Inc. Partners with Virginia Tech to Accelerate Bacterial and Fungal Microbiome-Based Product Development and Commercialization through A.I.
PR Newswire | March 7, 2024

Meet Electra, the robot that may one day paint your roads
Crain’s Cleveland Business | Feb. 20, 2024

Company co-founded by Case Western Reserve University researcher named finalist in South by Southwest pitch competition
The Daily | Feb. 19, 2024

AlensiaXR Series A Funding Round to Evolve Anatomical Instruction Using Holograms
BusinessWire | Feb. 1, 2024

CES 2024: Most-ever inventors from Case Western Reserve to showcase their innovations at Las Vegas exhibition for 11th straight year
The Daily | Jan. 5, 2024


2023

Any Target, Every Time - How molecular “matchmaking” could pave the way for drug development to target the 85% of molecules considered undruggable.
Amgen.com | Nov. 28, 2023

Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
Luciddx.com | Oct. 31, 2023

NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
Nervgen.com | Oct. 23, 2023

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Nervgen.com | Sept. 25, 2023

When a Network Matters! Functional iPSC-derived Endothelial Cells Finally Arrive
Bioinformant | Sept. 18, 2023

‘Great news for patients:’ Breathing device from UH, CWRU to help more paralyzed patients
Cleveland.com | July 25, 2023

Two NE Ohio startups land Ohio Third Frontier grants
Crain's Cleveland Business | July 11, 2023

Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
PAVmed | May 11, 2023

Biomarkers and Balloons Help in the Fight Against Esophageal Cancer
AUTM | April 21, 2023

Lucid Diagnostics Reports Publication of Future Effective Foundational Local Coverage Determination by Medicare Administrative Contractor Noridian Healthcare Solutions
PAVmed | April 18, 2023

NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
NervGen | April 13, 2023

NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
NervGen | March 30, 2023

Biohm partners with Life Extension to design targeted microbiome supplements
NutraIngredients USA | March 16, 2023

CWRU creates company to market its HoloAnatomy software that teaches cadaver-free anatomy
Cleveland.com | March 15, 2023

Case Western Reserve University completes exclusive license agreement with Atlanta-based RORA Biologics Inc. for cancer and HIV therapy technologies
The Daily | March 8, 2023

BIOHM Probiotic Products Gain Investment from Valley Growth Ventures
The Business Journal Daily | March 8, 2023

Case Western Reserve University completes exclusive license agreement with Atlanta-based RORA Biologics Inc. for cancer and HIV therapy technologies
The Daily | Feb. 23, 2023

CWRU reaches international licensing deal with Atlanta company
Crain's Cleveland Business | Feb. 23, 2023

Lucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event
PAVmed | Feb. 15, 2023

National Academy of Inventors names eight Case Western Reserve University researchers to 2023 class of senior members
The Daily | Feb. 14, 2023

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen | Feb. 14, 2023

Bringing ideas to market: CWRU researchers turn discoveries into inventions
The Daily | Feb. 13, 2023

St. Joseph students studying anatomy in virtual reality
Fox 8 WJW | Feb. 7, 2023

This Week In XR: $18 Million For Gemba VR Training, Dreamscape Learn Spins Off With $20 Million
Forbes | Jan. 27, 2023

$578 million for Greater Cleveland’s startups: These 23 companies raised the most cash in 2022
The Plain Dealer | Jan. 26, 2023

New company from Case Western Reserve University helps medical students learn anatomy through holographic imagery
Ideastream Public Media | Jan. 26, 2023

Making blood in the lab: Facing donor shortages and storage limitations, researchers are developing synthetic red blood cells, platelets, and plasma and combining them into artificial blood.
Drug Discovery and Development | Jan. 18, 2023

Case Western Reserve University launches Ilumis: Startup to accelerate and scale adoption of pioneering HoloAnatomy software to transform the way students learn human anatomy
The Daily | Jan. 17, 2023


2022

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
Lucid Diagnostics | Dec. 8, 2022

Researchers Markowitz, Tyler elected fellows for 2022 class of National Academy of Inventors
The Daily | Dec. 8, 2022

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
Lucid Diagnostics | Dec. 1, 2022

Exclusive license agreement with Case Western Reserve University for Core-NK platform
Chimeric Therapeutics | Nov. 21, 2022

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
PAVmed | Dec. 1, 2022

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
PAVmed | Dec. 8, 2022

Researchers Markowitz, Tyler elected fellows for 2022 class of National Academy of Inventors
The Daily | Dec. 8, 2022

Case Western Reserve University receives $1M state grant for technology start-up fund
The Daily | Nov. 21, 2022

Third Frontier Provides Funds to Accelerate Innovation
Ohio Department of Development | Oct. 18, 2022

NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291
NervGen | Oct. 25, 2022

A ‘game changer’ for people with sickle cell disease: Case Western Reserve University researcher, company, collaborating to develop blood test measuring the effects, potency of new gene therapies for sickle cell disease
The Daily | Sept. 14, 2022

Top faculty to be honored during CWRU’s inaugural Innovation Week
The Daily | Sept. 8, 2022

An inventive spirit, an impressive ranking
The Daily | Sept. 8, 2022

A ‘game changer’ for people with sickle cell disease
The Daily | Sept. 9, 2022

Folio Photonics Announces Breakthrough Multi-Layer Optical Disc Storage Technology to Enable Industry-Disruptive Cost, Cybersecurity and Sustainability Benefits
Folio Photonics | Aug. 30, 2022

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
PAVmed | Aug. 11, 2022

NervGen Pharma Reports Second Quarter 2022 Results and Provides Corporate Update
NervGen | Aug. 10, 2022

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
Lucid Diagnostics | Aug. 4, 2022

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
BusinessWire | Aug. 3, 2022

NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer's Disease at the 2022 Alzheimer's Association International Conference
NervGen | Aug. 2, 2022

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
PAVmed | Aug. 2, 2022

NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors
NervGen | July 14, 2022

RAD adds brain tumor technology to portfolio
Radiopharm Theranostics | June 9, 2022

Case Western Reserve University signs license agreement to bring artificial intelligence breakthroughs closer to cancer patient care
The Daily | May 25, 2022

Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
AccessWire | May 12, 2022

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
PAVmed | May 9, 2022

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
PAVmed | April 4, 2022

NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
NervGen | March 31, 2022

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study
PAVmed | March 24, 2022

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
PAVmed | March 23, 2022

NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
NervGen | March 15, 2022

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
PAVmed | March 3, 2022

Three Case Western Reserve University faculty elected as 2022 Senior Members of National Academy of Inventors
The Daily | Feb. 11, 2022

Case Western Reserve University grants exclusive license to Ionis Pharmaceuticals to advance antisense therapy for Pelizaeus-Merzbacher disease
The Daily | Jan. 27, 2022

Road-painting robot created in Northeast Ohio could save lives
News 5 Cleveland | Jan. 21, 2022

Case Western Reserve University partners with Produce Perks Midwest, expanding nutrition-incentive technology at farmers’ markets
The Daily | Jan. 20, 2022

CWRU On Track

Crain's Cleveland Business | Jan. 20, 2022

CWRU inks licensing deal to commercialize an imaging agent to aid in brain tumor surgery
Crain's Cleveland Business | Jan. 19, 2021

Cleveland-based RoadPrintz Inc. receives $1M from National Science Foundation to advance mobile robotic pavement-marking system

The Daily | Jan. 5, 2022


2021

NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
NervGen | Dec. 22, 2021

Zheng-Rong Lu elected fellow of National Academy of Inventors
The Daily | Dec. 22, 2021

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
PAVmed | Dec. 1, 2021

Chimeric Transforms Portfolio With a Clinically Validated, Off the Shelf, Natural Killer (NK) Cell Platform
Global NewsWire | Nov. 30, 2021

NervGen Pharma Corp. Closes Non-Brokered Private Placement
NervGen | Nov. 29, 2021

First Point-of-Care Test for Serious Hemoglobin Disorder, Beta Thalassemia, Provides New Weapon for the Front Lines of Healthcare Worldwide
Hemex Health | Nov. 24, 2021

NervGen Pharma Reports Third Quarter 2021 Results
NervGen | Nov. 18, 2021

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers
Lucid Diagnostics | Nov. 11, 2021

NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021
NervGen | Nov. 4, 2021

Lucid Diagnostics’ EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award
Lucid Diagnostics | Oct. 28, 2021

Case-Coulter Translational Research Partnership, with support provided by JobsOhio for the Cleveland Innovation District, awards $1.9 million in funding and support for promising biomedical engineering university technologies
The Daily | Oct. 20, 2021

NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting
NervGen | Oct. 18, 2021

Lucid Diagnostics Announces Pricing of Initial Public Offering
PAVmed | Oct. 13, 2021

Peak Nanosystems raises $25 million from Squadron Capital
Crain's Cleveland Business | Oct. 8, 2021

NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trails
NervGen Pharma | Sept. 27, 2021

Lucid Diagnostics, a medtech company with ties to Case Western Reserve University, plans to go public
Crain's Cleveland Business | Sept. 24, 2021

PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
PAVmed | Sept. 23, 2021

Lucid Diagnostics prepares to leave the PAVmed nest with $57M IPO filing
Fierce Biotech | Sept. 23, 2021

PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test
MyStrategist.com/MedTech-Strategist | Aug. 19, 2021

PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
Business Wire | Aug. 10, 2021

Nervgen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer’s Disease
Business Insider | Aug. 9, 2021

PAVmed: A Small Cap Puts Its Streamlined Development Model to the Test
MedTech Strategist | Aug. 2, 2021

Breakthrough Device ClotChip Moves Forward Toward Production
PRNewswire | July 22, 2021

Case Western Reserve University Licenses Rapid Malaria, Hemoglobin Disorder Tests
AUTM | July 16, 2021

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High Frequency Nerve Block System
Neuros Medical | June 29, 2021

Presidio Medical Announces New Executive Appointment
BusinessWire | June 28, 2020

NervGen Pharma: A “Blockbuster Drug” in the Making?
Stockhouse | June 28, 2021

Third Frontier awards more than $9 million in funding for Northeast Ohio
TechOhio, June 24, 2021

Case Western Reserve ranks 21st in the world for U.S. utility patents
The Daily | June 15, 2021

PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
PAVmed | June 10, 2021

NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer’s Disease Models
NervGen | June 10, 2021

MedLumics Closes Upsized (21.7M USD) Financing Round and Appoints New Chairman
MedLumics | May 28, 2021

PAVmed  Subsidiary  Lucid  Diagnostics Receives  CE  Mark  Certification  for  its EsoCheck®  Esophageal  Cell  Collection Device
PAVmed | May 26, 2021

NervGen Pharma Reports First Quarter 2021 Results
NervGen | May 20, 2021

A Quiet Student Startup Bursts Into the Big Time as Path Robotics Attracts $56 Million In New Investment
The Daily | May 7, 2021

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-29
NervGen | May 6, 2021

Case Western Reserve University-Developed Imaging Agent for MRI Prostate Cancer Detection Gets FDA Approval for Safety Trails, Set to Begin This Month in Columbus
The Daily | May 5, 2021

Ohio Third Frontier Commission bolsters Case Western Reserve University startup funding
The Daily | April 29, 2021

FDA Approves Tumor-Based MRI Contrast Agent for Prostate Cancer Detection
Diagnostic Imagining | April 25, 2021

NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
NervGen Pharma | April 22, 2021

First Clinical Trials Set for MRI Cancer Detection
Eurek Alert | April 22, 2021

CWRU Atelerix Sign Option License to Develop Therapeutic Approach to Opioid Crisis
Crain's Cleveland Business | April 20, 2021

Team players: Cleveland Innovation District is a group effort for local healthcare investment

FreshWater Cleveland | April 22, 2021

Cardialen Announces Positive Results From Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation
Business Wire | April 13, 2021

Journey to multi-million dollar Amgen acquisition required curiosity, collaboration and commercial expertise
The Daily | April 8, 2021

Case Western Reserve University biotech startup Rodeo Therapeutics Corp. sold to Amgen Inc.
The Daily | March 31, 2021

Amgen to Acquire Rodeo Therapeutics Corporation
PRNewswire | March 30, 2021

Preclinical Program Targeting 15-PGDH has Potential use in Broad Range of Therapeutic Applications Including Inflammatory Disease Indications
The PharmaLetter | March 30, 2021

Equalize 2021 Pitchers Announced
Equalize | Feb. 18, 2021

NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
NervGen | March 8, 2021

NervGen Pharma Provides Regulatory Update on Development Program for NVG-291
NervGen | March 2, 2021

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Result
PAVmed | Feb. 22, 2021

Rohan Akolkar Elected Senior Member of National Academy of Inventors
The Daily | Feb. 11, 2021

NervGen Pharma Adds Alzheimer’s Disease Patient Cohort to its Phase 1 Clinical Trial Program
NervGen | Jan. 27, 2021

NervGen’s 2020 in Review and the Plan Ahead
NervGen | Jan. 11, 2021

Neuros Medical Announces Key Milestones in the Quest Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical | Jan. 6, 2021

Neuros Medical Raises $38.5M in Series BB Funding for Completion of Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical | Jan. 6, 2021

Tevard, Zogenix Partner to Advance Gene Therapies for Genetic Epilepsies
Dravet Syndrome News | Jan. 5, 2021

NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
NervGen Pharma | Jan. 5, 2021